September 9, 2020
EO2401 is an innovative, off-the-shelf microbiome-antigen (‘OncoMimic’) based immunotherapy candidate EO2401 combines three ‘OncoMimics’ designed to trigger the immune system into recognizing tumor cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response Clinical trial with EO2401 now underway in two cancer indications: brain cancer (glioblastoma) and adrenal tumors Paris, France and Cambridge, MA,...


DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge